Genmab

	29/5 15:10 af Helge Larsen/PI-redaktør	Det kræver adgang til Asco Meeting Library for at se posters og videoer. Formoder at der dog dukker noget op på Twitter snart.
	29/5 15:09 af gdn55	Måske stilhed før storm?
	29/5 15:02 af E L	genmab-at-asco-2020.com/ (link)
	29/5 15:00 af E L	i thnk we had that data
	29/5 14:58 af E L	a bit on Amivanta (link)
	29/5 14:29 af Parasitism	EL - fastest googler in the west, nothing yet?
	29/5 14:07 af gentogen	Måske nogen kan få lidt ud af denne slørede version...(link)
	29/5 13:43 af henrik48	Der er sandelig gjort plads til stigning... :-)
	29/5 13:25 af concillado	...it's the final countdown! :D
	29/5 13:22 af Michael Almskov	Darvin. Jeg tror de vågner 14.05 ????
	29/5 13:08 af Darvin	Det er sgu nogle nærige og dovne investorer vi har omkring DK aktier. Både Gen og Bavarian halter da lidt :-D
	29/5 13:07 af E L	"Giving azacitidine may help increase the levels of CD38 on the tumor cells to increase the function of daratumumab to attach to those tumor cells to help destroy them."
	29/5 13:07 af E L	small New trial : Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab (link)
	29/5 11:23 af GeorgeBest	ja, men jeg skulle først trykke på "åbn chat", det var det jeg ikke kunne huske, eller tak :-)
	29/5 11:23 af Skyggen	Ok fint ;-)
	29/5 11:22 af Skyggen	GB@ Gemmer sig nede i højre hjørne af skærmen
	29/5 11:19 af GeorgeBest	har fundet den
	29/5 11:10 af GeorgeBest	hvordan åbner man chat vinduet på iphone?
	29/5 11:08 af bikube	KWC - det er sidste dag i måneden, så der er nok nogle fonde, der skal have skiftet ud i depoterne efter den stigning, vi har set.
	29/5 10:11 af gentogen	Beginning Friday, May 29 at 8:00 AM ET Oral, Poster Discussion, and Poster Sessions, as well as track-based Clinical Science Symposia, will be available on demand. Registrants will have exclusive access to hundreds of video and slide presentations, as well as discussant commentary for 180 days
	29/5 10:06 af Legolas23	Gap-luk
	29/5 10:05 af KWC	- Så gevinst hjemtagning før næste stigning ;-)
	29/5 09:52 af GeorgeBest	14:00 CET. Leading oncologists will surely post results on twitter shortly after
	29/5 09:51 af E L	we are +6 i think, so 14.00

	29/5 09:51 af E L	Genmab is presenting data at #ASCO20, including data from the epcoritamab (DuoBody®-CD3xCD20) Phase 1/2 dose-escalation study on Friday May 29 at 8 AM EDT.
	29/5 09:49 af Sukkeralf	Will we see epco data before close today - anybody knows ?
	29/5 09:48 af E L	i was responding to GB. No idea what this crazy stock will do on a day basis. Month-end, Monday closed, who knows...
	29/5 09:46 af AaBforever	sure..
	29/5 09:43 af E L	yes
	29/5 09:43 af AaBforever	Mon den holder + i dag?
	29/5 09:34 af GeorgeBest	That must be health authorities worldwide I presume?
	29/5 09:33 af GeorgeBest	Janssen, which obtained an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab in 2012, will discuss with health authorities the potential for a regulatory submission for this indication.
	29/5 09:30 af GeorgeBest	Do anyone know how far away approval for Amy in EU and Japan is?
	29/5 09:28 af GeorgeBest	I think you are right Darwin, because as I understand Jan yesterday, there will be no competition in Amy, in contrary to MM where there are some competion especially in first line
	29/5 09:27 af Darvin	not scientifically calculated however
	29/5 09:25 af Darvin	E L ok - then if one use a simple calculation method, it should end up around 1 billion for Genmab/JJ :-) OR ?
	29/5 09:14 af bikube	ATH er løftet en hel% til 2140.
	29/5 09:05 af E L	but looking forward to the real data; not so sure yet if there is good renal response
	29/5 09:04 af E L	the 'good' thing for Dara in my opinion is that there really isn't much of an alternative and we can roll it out very fast now; every MD already knows Dara & it's risk profile
	29/5 09:04 af Sukkeralf	Lad os så få den epcoritamab deal - og data
	29/5 09:00 af E L	compare MM -26,000 people estimated newly diagnosed with and 13,650 estimated to have died from multiple myeloma in the U.S. in 2018 -160,000 people estimated diagnosed with and 106,000 estimated to have died from multiple myeloma worldwide in 2018.
	29/5 08:59 af E L	annual report p 26 -3,000-4,000 approximate number of new cases diagnosed annually, making AL amyloidosis the most common type of amyloidosis in the U.S - An estimated 16,000 people in the United States suffer from amyloidosis. - 12-15% of multiple myeloma patients develop light chain (AL) amyloidosis.
	29/5 08:56 af Darvin	Hvis ikke jeg husker forkert har andre talt om det dobbelte af hvad Søren siger.
	29/5 08:53 af Legolas23	Premarket siger en kursstart på 2110
	29/5 08:49 af Parasitism	Det skulle man tro. Bygger hans topsalgsestimat på de 500 mio., så også kun for USA?
	29/5 08:35 af Mogan	Søren Løntoft, siger at AL-amyloidose er en mere sjælden sygdom, med 3000-4000 nye diagnosticerede om året i USA. Men vel også potentiale i andre lande?
	29/5 08:22 af bibob	God morgen. :-)
	29/5 08:16 af Helge Larsen/PI-redaktør	Pensionist...Aktiesnakken.
	29/5 08:16 af Sukkeralf	Lad det bare blive Janssen og BMS der står for MM - BMS førende pt men Janssen overtaget taktstokken stille og roligt
	29/5 08:15 af Sukkeralf	Ja sjovt med sådan et abstract på late breaker, hvilket jo igen afliver tanken om at alle præsentationer er med positive data. Eller dette er jo positivt for Velcade og pris på behandling fremadrettet.